Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Amortizatization of Intangibles (2016 - 2025)

Viking Therapeutics' Amortizatization of Intangibles history spans 12 years, with the latest figure at $94000.0 for Q4 2025.

  • For Q4 2025, Amortizatization of Intangibles fell 14.55% year-over-year to $94000.0; the TTM value through Dec 2025 reached $431000.0, up 24.57%, while the annual FY2025 figure was $431000.0, 24.57% up from the prior year.
  • Amortizatization of Intangibles for Q4 2025 was $94000.0 at Viking Therapeutics, down from $114000.0 in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $5.4 million in Q3 2023 and bottomed at -$5.2 million in Q4 2023.
  • The 5-year median for Amortizatization of Intangibles is $75000.0 (2021), against an average of -$202700.0.
  • The largest annual shift saw Amortizatization of Intangibles tumbled 5911.27% in 2021 before it surged 4133.78% in 2025.
  • A 5-year view of Amortizatization of Intangibles shows it stood at -$4.1 million in 2021, then surged by 65.2% to -$1.4 million in 2022, then tumbled by 262.67% to -$5.2 million in 2023, then surged by 102.11% to $110000.0 in 2024, then fell by 14.55% to $94000.0 in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Amortizatization of Intangibles are $94000.0 (Q4 2025), $114000.0 (Q3 2025), and -$2.9 million (Q2 2025).